Into the Clinic With Nivolumab and Pembrolizumab

In 2015, the US Food and Drug Administration approved the use of nivolumab for treatment of squamous and nonsquamous non-small cell lung cancer (NSCLC) and pembrolizumab for use in patients with NSCLC tumors that express PD-L1. This commentary discusses issues with these two drugs relative to best p...

Descripción completa

Detalles Bibliográficos
Autores principales: Shu, Catherine A., Rizvi, Naiyer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861376/
https://www.ncbi.nlm.nih.gov/pubmed/27026678
http://dx.doi.org/10.1634/theoncologist.2016-0099
Descripción
Sumario:In 2015, the US Food and Drug Administration approved the use of nivolumab for treatment of squamous and nonsquamous non-small cell lung cancer (NSCLC) and pembrolizumab for use in patients with NSCLC tumors that express PD-L1. This commentary discusses issues with these two drugs relative to best practices and target populations.

Ejemplares similares